德琪医药-B(06996.HK) 公布，董事会于昨日(7日)已决议动用股份购回授权，并根据市况不时于公开市场
按最高总价4,000万元购回股份。另外，董事会可根据购回当时的市况及集团的资本管理需要，后续将购回的股份注销或由公司持作库存股份。
目前，公司尚未购回其任何股份。(js/j)(港股报价延迟最少十五分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.